Athenex is a global specialty oncology pharmaceutical company founded in 2003 and headquartered in the United States. The company is dedicated to the development and commercialization of next generation therapies for cancer diseases and supportive therapies. With a focus on delivering innovative drugs that can have a life-changing impact on cancer patients, Athenex operates medical technology innovation centers and a unique manufacturing supply chain across both China and North America. Through its connected innovation and manufacturing supply chain presence, Athenex can identify, develop, and deliver proprietary medical technology across continents and multiple regulatory environments. The company's last investment of $30.00MPost-IPO Equity was made on 11 August 2022, marking a significant milestone in its growth. Although the specific investors for this round are not disclosed, it underscores confidence in Athenex's potential within the biotechnology and pharmaceutical industries.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $30.00M | - | 11 Aug 2022 | |
| Post-IPO Equity | $60.00M | 1 |
|
05 Dec 2019 |
| Post-IPO Equity | $100.00M | 2 |
|
06 May 2019 |
| Post-IPO Equity | $50.00M | 1 |
|
02 Jul 2018 |
| Private Equity Round | $48.10M | 1 |
|
20 May 2015 |
No recent news or press coverage available for Athenex.
We care about your data, and we'd love to use cookies make your experience better.
